-
- Description: Cytogen Corporation is a biopharmaceutical company dedicated to improving the lives of patients with cancer by acquiring, developing and commercializing molecules targeting the sites and stages of cancer progression. Its marketed products include Quadramet (samarium Sm-153 lexidronam injection) and Prostascint (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide in the United States. The Company also has exclusive United States marketing rights to Combidex (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (formerly Code 7228) for oncology applications in the United States. Cytogen is also developing therapeutics targeting prostate-specific membrane antigen (Psma), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Cytogen Corporation is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing and commercializing a portfolio of oncology products. General Information Year established 1986
- More Products No Keyword available...
- About Owner No Owner Type Present...
-
